Symbols

SLNO

Soleno Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 6

Bearish signal 0

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

High Cash/net Profit Ratio

EPS Beats Expectation

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SLNO

Soleno Therapeutics, Inc.

A clinical-stage biopharmaceutical company that currently developing a once-daily oral tablet for the treatment of Prader-Willi syndrome

Industry

Life Science Tools and Services

Established Date

08/25/1999

Listing Date

11/13/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

182

Fiscal Year Ends

12-31

Website

www.soleno.life

Security Type

Common stock

Office address

100 Marine Parkway, Suite 400, Redwood City, California 94065

Business

Introduction

Soleno Therapeutics, Inc., was incorporated in Delaware on August 25, 1999. The company focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company's lead drug candidate, DCCR (diazachol) sustained-release tablets, is a potent ATP-sensitive potassium (KATP) channel activator.

Company Financials

EPS

SLNO has released its 2025 Q4 earnings. EPS was reported at 0.8, versus the expected 0.61, beating expectations. The chart below visualizes how SLNO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SLNO has released its 2025 Q4 earnings report, with revenue of 91.73M, reflecting a YoY change of NaN%, and net profit of 43.36M, showing a YoY change of 177.45%. The Sankey diagram below clearly presents SLNO's revenue sources and cost distribution.